Rivaroxaban is a recently developed factor Xa (FXa) inhibitor for the prevention and
treatment of thromboembolic disease. There are no data on dose adjustments in patients with
severe chronic renal failure. It's use is therefore not recommended in this patient
population. The present study aims to asses in 12 hemodialysis patients that require
prevention of deep vein thrombosis:
1. the AUC and Cmax of 10 mg rivaroxaban
2. the effect of 10 mg rivaroxaban on coagulation assays
3. the effect of a single dialysis session on plasma levels of rivaroxaban and on anti-Xa
levels
4. the safety and tolerability of rivaroxaban